Nonclinical models for antituberculosis drug development: a landscape analysis.
about
Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunitiesAssessment of treatment response in tuberculosisChallenges in the clinical assessment of novel tuberculosis drugs.A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment durationSterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of CaseumMoxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.Assessment of bactericidal drug activity and treatment outcome in a mouse tuberculosis model using a clinical Beijing strain.Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosisPharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.Improving treatment outcome assessment in a mouse tuberculosis model.Galleria mellonella - a novel infection model for the Mycobacterium tuberculosis complex
P2860
Q28072376-4577BE05-4930-4DA1-8B77-F95D57303983Q28384421-CE444C9D-D6EF-4768-ADA7-BBAD0552D0DEQ30251933-887A1C90-D0C7-4BF2-9D6B-29AC8D8C6AC7Q30275728-1B8C3DDD-BD84-4281-A7AE-C340A8ADC7E7Q30377051-3A278DBA-7E1A-41A4-8123-A61EC959ED64Q36571928-3E20A014-174C-45DA-B4B3-9785D5399EAFQ36571981-38DA1547-0D6C-4A27-8ED8-873B2C1DA818Q36933441-43042754-0D92-4520-9ADB-B31430958107Q37339294-375B37DF-7FB3-45D2-A1BD-9EF1EEBE2DE8Q38652464-CDEE1136-B748-40C6-9087-D558AD7C68E8Q38979626-6634B10D-3F2E-47A4-9F9F-E2ECECA311E7Q40065397-BF0B289F-D23B-43EF-82B0-E58E4C0D41D4Q40139991-A6CD2F73-1BBB-4052-805C-B690CA201013Q40363572-0363127E-ED59-496E-A5D5-AF32C3681995Q40679730-B5B07E36-B9F2-488F-95DF-3F13BD7928BCQ41082086-9E6195EC-75F2-48F0-BE3E-C23EE6F27E80Q42263053-F91D05E2-5820-4C3E-B9D9-A23C902576ABQ52606539-51C4E079-83D7-40C8-BD33-0492FA11B44AQ54239058-266B29E0-2B1B-47AF-B54B-C119D914BEC6Q58806135-46A30E8F-878B-4F10-B7CE-16AF85FD9834
P2860
Nonclinical models for antituberculosis drug development: a landscape analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Nonclinical models for antituberculosis drug development: a landscape analysis.
@en
type
label
Nonclinical models for antituberculosis drug development: a landscape analysis.
@en
prefLabel
Nonclinical models for antituberculosis drug development: a landscape analysis.
@en
P2093
P2860
P356
P1476
Nonclinical models for antituberculosis drug development: a landscape analysis.
@en
P2093
Anne J Lenaerts
Debra Hanna
Eric Nuermberger
Klaus Romero
P2860
P304
P356
10.1093/INFDIS/JIV183
P407
P478
211 Suppl 3
P577
2015-06-01T00:00:00Z